- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03674658
Propafenone in the Treatment of Atrial Fibrillation
An Open-Label Randomized Study of Propafenone in the Treatment of Atrial Fibrillation
Study Overview
Detailed Description
This is a open label randomized, multi-center study conducted in Taiwan. The study aims to evaluate the effectiveness and safety of oral Rhynorm (A drug) and Rytmonorm (B drug) for the conversion of paroxysmal AF and is designed to evaluate the improvement in sinus rhythm restoration after the treatment with Rhynorm (A drug) and Rytmonorm (B drug) for 24 weeks.
This study comprised of three phases: a screening phase, a washout run-in qualifying phase lasting about 7 days, and a treatment phase of 24 weeks. A total of 60 evaluable subjects is planned to be enrolled. With an estimation of 20% dropout rate, 72 patients will be enrolled to reach 60 evaluable patients at the end of study. After screening for eligibility, the eligible subjects will be randomly assigned to either of the two gruop. The two-group are shown in the following table.
Group Treatment Drug Group A Rhynorm (A drug) Group B Rytmonorm (B drug) Patients with arrhythmia will be screened for eligibility after providing informed consent. Patients present with the symptoms of arrhythmia after withdrawn from other prohibited anti-AF agents for at least 7 days and completed run-in period event recorded will be qualified for entering this study and will be randomized to Rhynorm (A drug) treatment group or Rytmonorm (B drug) reference drud group in a 1:1 ratio.
The clinical evaluation will be recorded during the study period. Before treating with Rhynorm (A drug) and Rytmonorm (B drug), the physical examination and condition will be tracked and recorded for at least 7 days as the historical data.
During the treatment period, the subjects still had a routine OPD visit. Record symptom event and event recorder monitoring on OPD visit.
Safety assessments on all randomized subjects include adverse events, vital signs, and laboratory tests (hematology and biochemistry). Any adverse events, symptom events and concomitant medications/therapies will be recorded on the CRFs throughout the study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kaohsiung, Taiwan
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who are 20~80 years of age
- Recurrent AF patients
- Patients with paroxysmal atrial fibrillation
Patients diagnosed with one of the ECG monitoring within 12 months prior screening visit:
- 12-lead electrocardiogram
- ECG used to make a 30 second one of recording
- 24 hours ECG (Holter Monitor)
- Long term ECG (Event Monitor)
- Patient may be receiving stable dose of propafenone since at least 4 weeks prior screening visit.
- Agree to and are able to follow the study procedures
- Understand the nature of the study, and have signed informed consent forms
Exclusion Criteria:
- Permanent or persistent AF
Any of the following heart disease:
- New York Heart Association class III or IV angina pectoris or heart failure
- previous electrocardiographic evidence of second- or third-degree atrioventricular block;
- Sinus node disease, AV conduction disturbance or bundle branch block in the absence of an artificial pacemaker
- Hemodynamic moderate valvular heart disease (stenosis and/or incompetent; regurgitation)
- Brugada syndrome
- Left ventricular EF< 50%
- Acute myocardial infarction or unstable angina within the previous 12 months
- Cardiogenic shock (excluding arrhythrmia shock) within the previous 12 months
- Acute pericarditis or myocarditis within the previous 6 months
- Cardiac or thoracic surgery within the previous 6 months
- Symptomatic Bradycardia (heart rate less than 50 beats per minute)
- Hemodynamic instability, defined as hypotension (SBP < 90 mm Hg)
- Hyperthyroidism
- Bronchospastic disorders or severe obstructive pulmonary disease
- Correctable AF for other reasons
- Marked electrolyte imbalance
Patients with clinically significant abnormalities in the following laboratory parameters:
- AST or ALT ≥ 3X upper limit of normal (ULN)
- Total bilirubin ≥ 2X ULN
- Creatinine ≥ 2.5 mg/dL
- Hemoglobin < 10 g/dL
- Platelet < 100,000/uL
- Patients with known contraindication or history of allergy to Propafenone.
- Female patients who are pregnant or lactating.
- Female patients of child-bearing potentiality who do not agree to use an effective method of contraception during the study
- Patients currently participating in any drug related clinical trial within 30 days
- Patients with propagating factor (e.g. Alcohol Abuse induced AF)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A drug
Rhynorm(A drug)
|
oral, TID
Other Names:
|
Active Comparator: B drug
Rytmonorm (B drug)
|
oral, TID
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
proportion of patients with recurrent AF
Time Frame: 24 weeks treatment
|
To compare the effect of Rhynorm (A drug) and Rytmonorm (B drug) over 24 weeks of treatment based on the proportion of patients with recurrent AF
|
24 weeks treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TSHRH1801-P
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on Propafenone
-
Vanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI)Terminated
-
Valduce HospitalCompletedAtrial FibrillationItaly
-
Ultragenyx Pharmaceutical IncNovartis; Mereo BioPharmaWithdrawnChronic-kidney Disease Stage 5D on Stable Hemodialysis
-
Shandong UniversityRecruiting
-
GlaxoSmithKlineCompleted
-
University of PennsylvaniaCompletedAtrial FibrillationUnited States
-
Ospedale San DonatoUnknownVentricular Tachycardia | Ventricular Premature ComplexesItaly
-
Yong Seog OhWithdrawn
-
Samsung Medical CenterCompletedAtrial FibrillationKorea, Republic of
-
Jason AndradeMedtronic; Ottawa Heart Institute Research Corporation; Baylis Medical CompanyActive, not recruitingAtrial FibrillationCanada